Current stock page

Financial Data

VKTX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

VKTXViking Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

BearishEdge 7/10
$29.22+$1.64 (+5.95%)

Latest quote

  • Momentum
    47
  • Value
    —
  • Quality
    33
  • Risk resilience
    41
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit$0$0$0-$94K-$114K$0$0$0
Operating Income-$187.11M-$132.6M-$164.13M-$164.74M-$98.56M-$74.57M-$55.47M-$46.24M
Net Income-$183.19M-$128.02M-$158.33M-$157.66M-$90.79M-$65.56M-$45.63M-$35.42M
EPS-$1.55-$1.1-$1.37-$1.38-$0.81-$0.58-$0.41-$0.32
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$138.19M-$125.17M-$113.98M-$85.29M-$94M-$47.06M-$52.33M-$31.18M
Capital Expenditure$0$0$0$0$0$0$0$0
Free Cash Flow-$138.19M-$125.17M-$113.98M-$85.29M-$94M-$47.06M-$52.33M-$31.18M
Net Cash Provided By Operating Activities-$138.19M-$125.17M-$113.98M-$85.29M-$94M-$47.06M-$52.33M-$31.18M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$977.17M$521.9M$608.24M$715.73M$739.42M$827.85M$866.99M$908.32M
Total Debt$254.69M$4.09M$0$137K$755K$878K$1M$1.12M
Cash And Cash Equivalents$677.61M$125.75M$118.12M$165.81M$100.38M$33.88M$37.94M$26.68M
Total Liabilities$388.57M$113.58M$106.33M$76.67M$26.39M$32.39M$20.08M$28.04M
Total Stockholders Equity$588.6M$408.32M$501.92M$639.06M$713.03M$795.46M$846.92M$880.28M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio5.099.497.215.094.954.713.43.52
P/S ratio————————
Debt To Equity0.430.01000000
Free Cash Flow Yield-15.45%-10.80%-9.40%-8.56%-6.36%-4.07%-4.66%-2.83%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio5.099.497.215.094.954.713.43.52
P/S ratio————————
Return On Equity-106.56%-130.98%-94.11%-56.28%-33.29%-21.57%-15.14%-12.49%
Debt To Equity0.430.01000000

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-5.41x
Pb5.86x
EPS Growth Yoy-91.36%
Gross Margin0.00%
Operating Margin0.00%
ROE-117.35%
ROIC-76.91%
Debt To Equity0.43
FCF Yield-12.42%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$29.22
Volume8.87M
RSI (14)54.98
MACD-0.09
MACD signal-0.6
MACD histogram0.51
ADX (14)13.74
SMA (50)$29.33
SMA (200)$32.17
ATR (14)$1.83
Historical volatility (annualized)69.69%
Volume (20-day average)4.2M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score41/100
Beta1.29
Annual volatility69.18%
Max Drawdown-42.53%
Sharpe Ratio-0.15
VaR (95%, 1-day)-5.56%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

VKTX Financial Data FAQ

What is Viking Therapeutics, Inc.'s revenue?

Viking Therapeutics, Inc.'s revenue is one of the core financial data points for VKTX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Viking Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Viking Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is VKTX's EPS?

VKTX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Viking Therapeutics, Inc.'s net income?

Viking Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Viking Therapeutics, Inc. generate?

Free cash flow shows how much cash Viking Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Viking Therapeutics, Inc. have?

Cash and debt help frame VKTX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.